Creo Medical Group up after early health economics data

By
0 mins. to read
Creo Medical Group up after early health economics data

Shares in AIM-listed medical device manufacturer Creo Medical Group (LON:CREO) were up by 15.47% to 177.24p (as of 15:05 BST) after initial data showed that one of its devices can save £5,000 per patient relative to a traditional surgical procedure. Full data will be published in October, but the initial cohort suggested that more than £400,000 had been saved by using Creo’s endoscopy tool to remove pre-cancerous gastro-intestinal lesions under sedation rather than general anaesthetic.

CEO Greg Gulliford commented: “We are pleased that the initial positive NHS health economics data further supports and validates the adoption of Speedboat procedures against the current standard of care, with the savings demonstrated being greater than were originally anticipated in our original i4i funding applications. The roll-out of our technology throughout the NHS, supported by our recently announced commercialisation agreement with the Department for Health, will empower endoscopists and surgeons to change the way they operate, bring significant benefits to their patients and releases funding for trusts to be deployed elsewhere“.

On 7th July, we will be running a Q&A webinar with the one and only Evil Knievil (Aka Simon Cawkwell). Please share a question for Evil below and we’ll try to answer as many as possible in the live webinar. Sign up for the webinar here.

Are you going to take part in Evil's webinar?


Comments (1)

  • Ian Basford says:

    I think may be bit misleading. This procedure is often already done under sedation and has been for many years. Sometimes even sedation is not necessary. So where is the break through?

Leave a Reply

Your email address will not be published. Required fields are marked *